The discovery and development of atorvastatin, a potent novel hypolipidemic agent (Q33963546)

30 July 2017

1 reference

title

The discovery and development of atorvastatin, a potent novel hypolipidemic agent (English)

1 reference

30 July 2017

Bruce D Roth

1

1 reference

30 July 2017

publication date

1 January 2002

1 reference

Progress in medicinal chemistry

30 July 2017

published in

1 reference

30 July 2017

volume

40

1 reference

30 July 2017

page(s)

1-22

1 reference

The Biological Synthesis of Cholesterol

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Cataracts in Patients Treated with Triparanol

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Inhibition of cholesterol biosynthesis in man

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Hypocholesterolemic Agents II: Inhibition of β-Hydroxy-β-methylglutaryl Coenzyme A Reductase by Arylalkyl Hydrogen Succinates and Glutarates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Monacolin K, a new hypocholesterolemic agent produced by a Monascus species.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Microbial hydroxylation of ML-236B (compactin) and monacolin K (MB-530B)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 3. 7-(3,5-Disubstituted [1,1'-biphenyl]-2-yl)-3,5-dihydroxy-6-heptenoic acids and their lactone derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Einwirkung des Diacetbernsteinsäureesters auf Ammoniak und primäre Aminbasen

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Synthese von Thiophen- und Pyrrolderivaten

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Catalyzed Addition of Aldehydes to Activated Double Bonds?A New Synthetic Approach

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Subacute Toxicity of a Halogenated Pyrrole Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor in Wistar Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Preclinical evaluation of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2 H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

(R)- and (S)-2-acetoxy-1,1,2-triphenylethanol - effective synthetic equivalents of a chiral acetate enolate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970080-8

7 January 2021

10.1016/S0079-6468(08)70080-8

Identifiers

DOI

0 references

1 reference